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Abstract 
We present for the first time a 40-year-old
male patient with a 20 year history of occupa-
tional  exposure  to  radiation  as  a  nuclear
power  plant  worker,  who  developed  FIP1L1-
PDGFRA-positive  chronic  eosinophilic
leukemia  27  months  after  radiotherapy  for
testicular seminoma. After an one-year histo-
ry of dry cough, itching and night sweats, the
patient presented with an elevated leukocyte
count  with  absolute  eosinophilia  of
14.2x109/L,  bone  marrow  and  lymph  node
involvement. Treatment with Imatinib was ini-
tiated,  resulting  in  complete  hematological
remission  at  the  sixth  month  and  complete
molecular response by nested primers reverse
transcription polymerase chain reaction – at
the end of the first year. This case contributes
to the clinical heterogeneity of a rare entity
such as FIP1L1-PDGFA-positive myeloprolifer-
ative neoplasms, and for the possible role of
occupational and therapeutic radiation, rais-
ing the question if one or both of them might
be the causative factor. 
Introduction
The fusion gene FIP1L1-PDGFRA, contain-
ing regions of FIP1-like 1 (FIP1L1) gene and
the  Platelet-Derived  Growth  Factor  Receptor
Alpha (PDGFRA) gene as a result of the inter-
stitial cryptic deletion on chromosome 4q12
[del(4)(q12g12)],  is  considered  a  recurrent
molecular  abnormality  in  patients  with
eosinophilia-associated  myeloproliferative
neoplasms  (MPNs).  The  hymeric  product  of
FIP1L1-PDGFRA acts as a constitutively active
tyrosine kinase, however the precise underly-
ing  molecular  mechanisms  of  FIP1L1-
PDGFRA–mediated malignant transformation
are still incompletely understood.1
According  to  the  revised  World  Health
Organization (WHO) Classification of Tumors
of  Hematopoietic  and  Lymphoid  Tissues
(2008),  neoplasms  bearing  the  FIP1L1-
PDGFRA rearrangements  are  defined  as  a
rare,  separate  disease  entity.  Clinically,  the
disease is manifested most often as chronic
eosinophilic  leukemia  (CEL),  but  also  as
acute  myeloid  leukemia  (AML)  or  T  lym-
phoblastic lymphoma, or both simultaneously.2
As a rule, FIP1L1-PDGFRA-positive MPNs are
presented as de novo malignancy, and only two
cases following cytotoxic chemotherapy have
been reported as therapy-related so far.2,3 To
our knowledge, FIP1L1-PDGFRA-positive dis-
ease  after  radiation  exposure  has  not  been
published yet. 
In this study we present for the first time a
patient with a 20 year history of occupational
exposure to radiation, who developed FIP1L1-
PDGFRA-positive CEL 27 months after radio-
therapy for testicular seminoma. 
Case Report
A  40-year-old  male  nuclear  power  plant
worker was referred to The National Hospital
for  Active  Treatment  of  Hematological
Diseases in Sofia (September 2009) for diag-
nostic  evaluation  of  leucocytosis  and
eosinophilia, detected ten months before his
admission to our hospital, and resistant to cor-
ticosteroid  therapy.  The  patient  had  a  one-
year  history  of  dry  cough,  predominantly  at
night,  itching  and  night  sweats.  Previous
medical history included testicular seminoma,
diagnosed 27 months earlier (June 2007) and
treated with surgery followed by irradiation to
the  para-aortic  and  high  iliac  lymph  nodes
with a total dose of 36 Gy. No hematological
abnormalities were observed during the whole
period of regular clinical and laboratory follow
up thereafter until December 2008, when the
routine blood tests revealed eosinophilia (23%
-  1.3x109/L)  with  a  normal  white  blood  cell
(WBC) count (5.6x109/L), which progressively
increased.  On  physical  examination  the
patient had no hepato- or splenomegaly, but a
single  enlarged  cervical  lymph  node.
Radiological  chest  studies  showed  signs  of
minor  interstitial  pulmonary  fibrosis  in  the
hilar regions and no lung infiltration. 
At the time of admission, laboratory tests
revealed  elevated  WBC  count  of  18.1¥109/L,
hemoglobin level of 128 g/L and platelet count
of  290¥109/L.  Peripheral  blood  differential
showed  78%  eosinophils  (14.2¥109/L),  14%
mature neutrophils (2.5¥109/L), 2% basophils
(0.36¥109/L), and 6% lymphocytes (1.1¥19/L).
Laboratory chemistry tests were within nor-
mal ranges. On aspirate smears bone marrow
was markedly hypercellular due to a prolifera-
tion of abnormal eosinophils accounting for
51% of all bone marrow cells, including 31.5%
eosinophilic  myelocytes  and  19.5%  mature
eosinophils. Most of the cells showed sparse
granulation  with  clear  areas  of  cytoplasm,
some  had  pathological  violet  granules  on
Giemsa stains (Figure 1/A). Eosinophils were
positive for myeloperoxidase and were nega-
tive  for  non-specific  esterase  and  toluidine
blau stains. Neutrophils were 7.5% of all cells,
erythroblasts  -  37.5%,  small  non-granular
blasts  were  1%  and  megakaryocytes  were
reduced.  Immunophenotyping  on  bone  mar-
row aspirate was performed by flow cytometry
using  three  color  combinations  of  commer-
cially available fluorescent dye labeled mono-
clonal antibodies (Becton Dickinson) and ery-
throcyte lyse and wash technique according to
manufacturer’s  instructions.  Samples  were
acquired and analyzed on a BD FACSCanto II
flowcytometer and FACSDiva software (Becton
Dickinson).  Expansion  of  eosinophils  with
high  FSC  and  SSC  and  high  expression  of
CD45 was found, that were positive for CD13,
CD33,  and  CD15,  and  negative  for  CD34,
CD117, CD64, CD14, and CD10, as well as for
major  lymphoid  lineage  associated  markers.
No aberrant antigen expression was detected.
Blast  cells  were  identified,  accounting  for
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2.6% of bone marrow cells showing myeloid
phenotype - positive for CD34, CD33, CD13,
CD117,  CD38.  Lymphoid  populations  were
within the normal ranges. An excision biopsy
of an enlarged cervical lymph node was per-
formed in order to exclude a concomitant lym-
phoid  neoplasm.  The  microscopic  examina-
tion revealed nodal architecture almost com-
pletely effaced. Though there was a prolifera-
tion of preserved follicles with activated ger-
minal  centers,  interfollicular  areas  showed
massive infiltration by eosinophils at various
stages of maturation as well as CD68-positive
histiocytes  and  densely  proliferating  small
vessels  confirmed  by  immunohistochemistry
for CD34 (Figure 1/B). Only few cells showed
positive  immunostaining  for  Mast  cell
tryptase. Unfortunately, at the time of admis-
sion the cytogenetic study was unsuccessful.
The subsequent analyses during the course of
treatment  revealed  normal  karyotype.
Molecular  analysis  on  RNA,  extracted  from
bone marrow and peripheral blood cells, using
Reverse  Transcription  Polymerase  Chain
Reaction (RT-PCR) revealed FIP1L1-PDGFRA
rearrangement  (Figure  1/C).  Screening  for
BCR-ABL rearrangements  and  JAK2 gene
V617F  mutation  was  negative.  Taking  into
account all above mentioned data, a diagnosis
of chronic eosinophilic leukemia with FIP1L1-
PDGFRA rearrangement  was  made  and
Imatinib treatment initiated with a daily dose
of  100  mg.  Normal  WBC  (4.3¥109/L)  and
eosinophil counts (1%) were achieved at the
second month of therapy, however the bone
marrow  aspirates  were  dry  until  6  months
when a significantly hypocellular bone mar-
row with a complete remission was found. No
FIP1L1-PDGFRA mRNA was detected by a sin-
gle round RT-PCR and at the end of the first
year a complete molecular response by nested
primers RT-PCR was registered. 
Discussion
Secondary malignancies are the most seri-
ous  complications  of  otherwise  successful
treatment  of  some  solid  tumors.
Myelodysplastic  syndromes  (MDS)  and  AML
are the most common therapy-related hemato-
logical  malignancies  and  a  large  amount  of
data is available regarding their epidemiology,
molecular pathogenesis, clinical behavior and
response to therapy. Secondary MPNs are sig-
nificantly  rarer.  Almost  all  of  these  cases,
reportedly more than 150 patients, present as
secondary BCR-ABL-positive chronic myeloge-
nous leukemia (CML).4 In contrast, secondary
BCR-ABL-negative MPNs have only been occa-
sionally observed. In a survey among 29,356
testicular  cancer  survivors,  621  secondary
cancers were found, and the only MPNs were
four  cases  of  CML.5 Similarly,  in  another
study,  a  review  of  463,618  cases  of  cancer
patients treated with chemotherapy and radio-
therapy, revealed 233 patients with hemato-
logical  malignancies  including  AML/MDS
(n=741), CML (n=178), chronic lymphocytic
leukemia  (CLL)  (n=253)  and  acute  lym-
phoblastic leukemia (n=61). Notably, no cases
of BCR-ABL-negative MPNs were identified.5
Herein, we report a patient who developed a
secondary  FIP1L1-PDGFRA-positive  CEL,  27
months after radiotherapy for testicular semi-
noma and 20 years of occupational exposure
at a power plant station. This case is of clini-
cal  interest  in  several  aspects.  Firstly,
although  more  than  a  hundred  cases  of
FIP1L1-PDGFRA-positive  MPNs  have  been
reported so far, only two of them were second-
ary to chemotherapy for a primary cancer.3,6 In
the  first  case,  FIP1L1-PDGFRA fusion  gene
was detected 11 years after 3 courses of com-
bination  chemotherapy  because  of  non
Hodgkin’s lymphoma and 3 years after therapy
with cyclophosphamide for hypereosinophylic
syndrome.3 In the second case, the molecular
abnormality was found 1 year after the appli-
cation  of  several  courses  of  multiagent
chemotherapy for Langerhans cell histyocyto-
sis.6 No radiotherapy-related FIP1L1-PDGFRA-
positive  MPN  has  been  reported  so  far.
Secondly, our patient has two radiation expo-
sure  events  -  occupational  and  therapeutic,
raising the question if one or both of them
might  be  the  causative  factor.  Though  it  is
well known that abdominal and pelvic irradia-
tion may produce eosinophilia, two facts are
against the hypothesis that radiotherapy has a
primary  role  in  the  secondary  malignancy
pathogenesis. In the reported case, the diag-
nosis of CEL was made only 27 months after
radiotherapy and this period was significantly
shorter than the 5-9 years or longer, reported
in  the  literature,  though  secondary  myeloid
malignancies have been reported after similar
or even shorter latency period.7 Besides, our
patient received a high dose of 36Gy, though
for  a  larger  volume  including  parts  of  the
abdomen and pelvis and the radiation-related
leukemia risk has proven to be considerably
lower at high doses due to cell killing.8
On the other hand, the patient’s long-term
occupational radiation exposure may not be
the only culprit as many studies have failed to
prove  greater  risk  for  hematological  neo-
plasms  among  nuclear  power  plant  workers
compared with national rates.9 Similarly, no
strong  evidence  for  increased  risk  of





Figure  1.  Morphological  and  molecular
characteristics of the reported patient with
FIP1L1-PDGFRA-positive  chronic
eosinophilic  leuekemia:  a)  blood  smear.
Increased number of abnormal eosinophils
in  the  field,  characterized  with  sparse
granulation and clear areas of cytoplasm,
some with pathological granules. (Wright-
Giemsa stain, x 1000); b) a biopsy of an
enlarged  cervical  lymph  node.  Nodal
architecture  almost  completely  effaced.
Though there was a proliferation of pre-
served follicles with actived germinal cen-
tres i), interfollicular areas ii) showed mas-
sive infiltration by eosinophils, histiocytes
and  densely  proliferating  small  vessels.
(Hematoxylin-eosin  staining,  x  400);  c)
positive  result  for  FIP1L1-PDGFRA
fusion  transcripts  after  nested  primers
PCR  on  cDNA  using  primers  pairs  i)
FIP1L1(ext)-F:  acctggtgctgatctttctgat  /
PDGFRA  (ext)-R:  tgagagcttgtttttcactgga
and  ii)  FIP1L1(int)-F:  aaagaggatac-
gaatgggacttg /PDGFRA (int) R: gggaccg-
gcttaatccatag:1 No  template  control;2
Direct  amplification  of  patient’s  cDNA
using internal primers;3 Re-amplification
of patient’s first round PCR product using
internal  primers;4 Negative  control  -
cDNA of a healthy person;5 Positive con-
trol - EOL-1 cell line.[Hematology Reports 2011; 3:e17]
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found among adult populations with low dose-
rate fractioned exposures after the Chernobyl
accident.10 However,  the  understanding  of
radiation biology has undergone a fundamen-
tal shift in paradigms away from deterministic
hit-effect relationships and towards complex
ongoing cellular responses such as increased
genomic  instability,  and  decreased  adaptive
responses observed at very low doses, and par-
ticularly  relevant  when  exposure  is  spread
over  a  period  of  time.  These  are  circum-
stances that are important to understanding
cancer risk associated with occupational radi-
ation exposures due to increased sensitivity to
physical, radiation and chemical agents and
modified  biological  effects.11 Therefore,  in
accordance with the hypothesis of two/multi-
ple-hits carcinogenesis,12 it seems more prob-
able that in our patient, the cumulative dose
or sequential exposure to both occupational
and therapeutic radiation have contributed to
the development of a FIP1L1-PDGFRA-positive
neoplasm. However, a question still remains
why no other similar cases have been reported
so far in thousands of occupational radiation
workers as well as in patients who have under-
gone radiation therapy. 
Several  factors  might  be  related  to  the
absence  of  reported  cases  of  FIP1L1-
PDGFRA(+) CEL. Firstly, CEL in general is a
very rare disease.2 Besides,  FIP1L1-PDGFRA
fusion  gene  has  been  discovered  not  long
ago13 and cannot be detected by conventional
cytogenetics, therefore, the respective abnor-
mality had not been tested routinely in a sig-
nificant  proportion  of  patients  and  the  true
incidence of FIP1L1-PDGFRA-positive cases is
still unknown. To our knowledge there is at
least one case of CEL, developed 6 years after
radiotherapy  for  thyroid  cancer,  reported  so
far. Interestingly, this patient was positive for
t(6;11)(q27;q23)/MLL-AF6, which is a typical
molecular  marker  of  AML,  but  at  that  time
FIP1L1-PDGFRA-rearrangement was not test-
ed.14 On the other hand, the risk of develop-
ment of secondary malignancies after radia-
tion exposure depends on a number of factors
- cumulative radiation dose received, the indi-
vidual genetic background, exposure to addi-
tional mutagenic factors, etc. that might vary
from case to case.  
In conclusion, this case contributes to the
clinical heterogeneity of a rare entity such as
FIP1L1-PDGFA  –  positive  myeloproliferative
neoplasms, and for the possible role of occupa-
tional and therapeutic radiation, raising the
question if one or both of them might be the
causative factor. 
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